The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ATVI, ATIP and SESN

NEW YORK, NY / ACCESSWIRE / September 1, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Activision Blizzard, Inc. (NASDAQ:ATVI)

Investors Affected : August 4, 2016 - July 27, 2021

A class action has commenced on behalf of certain shareholders in Activision Blizzard, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Activision Blizzard discriminated against women and minority employees; (2) Activision Blizzard fostered a pervasive "frat boy" workplace culture that continues to thrive; (3) numerous complaints about unlawful harassment,
discrimination, and retaliation were made to human resources personnel and executives which went unaddressed; (4) the pervasive culture of harassment, discrimination, and retaliation would result in serious impairments to Activision Blizzard's operations; (5) as a result of the foregoing, the Company was at greater risk of regulatory and legal scrutiny and enforcement, including that which would have a material adverse effect; (6) Activision Blizzard failed to inform shareholders that the California Department of Fair Employment and Housing had been investigating Activision Blizzard for harassment and discrimination; and (7) as a result, Defendants' statements about Activision Blizzard's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/activision-blizzard-inc-loss-submission-form/?id=19215&from=1

ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II (NYSE:ATIP)

This lawsuit is on behalf of investors who: (a) purchased or otherwise acquired ATI securities between April 1, 2021 and July 23, 2021, inclusive and/or (b) held FVAC Class A common stock as of May 24, 2021 and were eligible to vote at FVAC's June 15, 2021 special meeting.

A class action has commenced on behalf of certain shareholders in ATI Physical Therapy, Inc f/k/a Fortress Value Acquisition Corp II. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) ATI was experiencing attrition among its physical therapists; (2) ATI faced increasing competition for clinicians in the labor market; (3) as a result of the foregoing, the Company faced difficulties retaining therapists and incurred increased labor costs; (4) as a result of the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form/?id=19215&from=1

Sesen Bio, Inc. (NASDAQ:SESN)

Investors Affected : December 21, 2020 - August 17, 2021

A class action has commenced on behalf of certain shareholders in Sesen Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/sesen-bio-inc-loss-submission-form/?id=19215&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/662346/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-ATVI-ATIP-and-SESN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.